19562 Investors following Lupin. Share this News with them.
0
Like this story, share it with millions of investors on M3
Lupin Q2 PAT seen up 4% to Rs 223.3 cr
Pharmaceutical firm Lupin is likely to report a profit after tax of Rs 223.3 crore in the second quarter of FY12, a growth of 4% as compared to Rs 215 crore in the corresponding quarter of last fiscal.
Pharmaceutical firm Lupin is likely to report a profit after tax of Rs 223.3 crore in the second quarter of FY12, a growth of 4% as compared to Rs 215 crore in the corresponding quarter of last fiscal.
Revenues are seen going up by 15% to Rs 1,646 crore from Rs 1,434 crore during the same period.
EBITDA is likely to jump 6.6% to Rs 318.3 crore in the July-September quarter of FY12 versus Rs 299 crore in a year ago period.
Operating profit margin is expected to be at 19.3% versus 20.8% year-on-year.
Expectations
One offs from Salix/Medicis included - expected one offs to the tune of Rs 97 crore to Rs 100 crore
Topline fueled by domestic formulations, Japan + US
US could be impacted due to high base effect in the Generics segment due to Lotrel generic but expect branded formulations to continue their strong run
Cefdinir to be a key growth driver for the quarter due to exit of two competitors from the market
Company will benefit from full quarter sales of Levofloxacin
Lupin also had one OC launch during the quarter - Norethindrone (19 September 2011)
Also launched generic Fortamet at-risk towards the end of the quarter
India growth aided by tie up with Eli Lily to promote Huminsulin range of products
US brand business growth to be (27% of US sales) driven by pick up in Antara
Higher realisation in Cefdinir may have a positive impact on EBITDA margins.
